Compare GSK plc (GSK) vs JD.Com Inc (JD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs JD.Com Inc — how do they compare? GSK plc trades at $50.54 (market cap $102.60B), while JD.Com Inc trades at $31.51 (market cap $44.04B). The key difference: GSK plc is far larger — about 2.3× JD.Com Inc's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| GSK | JD | |
|---|---|---|
Market Cap | $102.60B | $44.04B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $36.17 |
52-Week Low | $38.96 | $25.19 |
Enterprise Value | $123.04B | $30.10B |
Dividend Yield | 3.57% | 3.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
JD.com trades at $31.46, down 6.01% over 24 hours, with technical indicators showing bullish momentum despite recent pressure. The company reported strong Q1 2026 earnings of $0.74 EPS, beating expectations by 30%, while revenue grew to $1.31 trillion in 2025. Analysts maintain a bullish consensus with 32 buy ratings and a $38.00 price target, representing 21% upside potential. Recent news highlights JD's upcoming Q2 earnings report on August 13, 2026, with expectations of 618 promotion benefits.
JD presents compelling value with a P/S ratio of 0.24 and consistent earnings beats, though net margins remain thin at 1.05%. Regulatory scrutiny of the Ceconomy acquisition and competitive pressures pose risks, but institutional accumulation and bullish technicals support further upside. The stock's current level near key support at $31 offers an attractive entry point ahead of Q2 results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
